Professional paper
Research on the efficacy of prophylactic use of Acidosalus® probiotic in women with recurrent cystitis
Višnja Škerk
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Rosa Ferinčević
; Marina Lab d.o.o., Zagreb, Hrvatska
Alemka Markotić
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Saša Andrašević
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Velimir Milošević
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Martina Vargović
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Miram Pasini
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Petra Turčić
; Farmaceutsko-biokemijski fakultet Sveučilišta u Zagrebu, Zagreb, Hrvatska
Josip Begovac
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Abstract
The aim of this prospective research was to investigate the efficacy of prophylactic use of probiotic Acidosalus® in women with recurrent cystitis.
Acidosalus® is a unique combination of Lactobacillus acidophilus, Lactobacillus rhamnosus and bifidobacteria in high therapeutic concentrations of live bacteria ready for multiplication. It consists of group B vitamins, folic acid, highly soluble lactates, potassium, iron, phosphorus, and has the possibility to produce antimicrobial substances - lactic and acetic acid, diacetyl, lactocidine, acidophilucin, acidocin and acidophylin.
The research was conducted at the Outpatient Department for Urogenital Infections of the University Hospital for Infectious Diseases „Dr. Fran Mihaljević“ in Zagreb in the period between 01.01.2006. until 31.12.2009.
We investigated 117 patients aged between 18 and 65 years with diagnosed recurrent cystitis – more than two episodes of cystitis in the past 6, i.e. more than three episodes in the past 12 months. The inclusion criteria were as follows: presence of symptoms of lower urinary tract infection (dysuria, polakisuria, urgency), identical microbiological finding of cervical swab and urinary culture, leukocyturia, ultrasound excluded urinary tract abnormality.
All patients received adequate antimicrobial therapy for 7 days and then were randomly divided into two groups. One group received Acidosalus® probiotic as a prophylaxis immediately after the end of antimicrobial therapy – and at least three months continuously received Acidosalus® orally with simultaneous vaginal administration of Acidosalus® vaginalettes for at least 7 days. Planned duration of prophylaxis was three months.
Follow up visit performed 1-2 weeks after completion of seven day course of antimicrobial therapy showed that all patients were clinically and bacteriologically cured. Until the follow up visit three months after completed 7-day antimicrobial therapy, recurrent episodes of cystitis were recorded in 3 (5,4%) out of a total of 56 women who received probiotic prophylaxis and in 11 (18,3%) out of a total of 61 women who did not receive probiotic prophylaxis.
Three months after completed 7-day course of antimicrobial therapy, uropathogen bacteria were more often detected in vagina of women who did not receive probiotic prophylaxis (in 44 out of a total of 50 monitored patients - 88%) than in women who did not receive probiotic prophylaxis (in 18 out of a total of 53 patients - 34%).
The results of this study have shown that prophylactic use of mixed probiotic culture present in medicinal product Acidosalus® in women with recurrent urinary tract infections is efficient and safe. We would like to stress the importance of simultaneous oral and vaginal application, by which we achieve regeneration and improved function of autochthonous intestinal and vaginal microflora, reduce a reservoir of uropathogen bacteria in intestines and boost immunity in general.
Keywords
Recurrent urinary tract infections; probiotics; Lactobacillus
Hrčak ID:
59787
URI
Publication date:
31.3.2010.
Visits: 5.584 *